Here are the DEF 14A proxy statements from Telomir Pharmaceuticals, Inc. (TELO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow TELO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TELO filings page.
Telomir Pharmaceuticals, Inc. is asking shareholders to vote at a virtual-only annual meeting on September 11, 2026, at 11:00 a.m. Eastern Time. Holders of 68,774,954 shares of common stock as of July 21, 2026 may vote; a quorum requires holders of 33.33% of outstanding shares present in person or by proxy.
Shareholders will vote on three items: electing four directors (including CEO and Chair Erez Aminov), ratifying Salberg & Company, P.A. as independent auditor for 2026, and approving a possible adjournment to solicit additional proxies. The Board recommends voting FOR all proposals. The proxy also details 2025 executive pay, with Mr. Aminov receiving total compensation of $4,880,350, a base salary increase to $500,000 effective January 1, 2026, and option repricing on 3,960,170 shares to an exercise price of $1.30. An equity incentive plan reserves 11,500,000 shares, and major holders include Brian McNulty at 26.93% and Mr. Aminov at 16.10% of common stock.